Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | IDE | P14735 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | CA12 | O43570 | 6/20 | 0.63 |
| ▸ | CA1 | P00915 | 6/20 | 0.63 |
| ▸ | CA2 | P00918 | 6/20 | 0.63 |
| ▸ | CA9 | Q16790 | 6/20 | 0.63 |
| ▸ | HLCS | P50747 | 6/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565406 | 1.00 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL5585656 | 1.00 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12424056 | 1.00 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL19514780 | 1.00 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL33865 | 1.00 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL10140211 | 1.00 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL14812382 | 0.99 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| Hydrazine SCHEMBL28140320 | 0.99 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL23863708 | 0.96 | TDP1 (0.65) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1024507 | 0.94 | HLCS (0.72) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030077616-A1 | Biomolecule characterization using mass spectrometry and affinity tags | CIPHERGEN BIOSYSTEMS, INC. (US) | 2003-04-24 | — | — | US | claimed |
| US-20240024489-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | INSTITUT PASTEUR (FR) | 2024-01-25 | — | — | US | disclosed |
| WO-2022106703-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | INSTITUT PASTEUR (FR) | 2022-05-27 | — | — | WO | disclosed |
| US-9134318-B2 | Detection of oxidized polypeptides | PURDUE RESEARCH FOUNDATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140024124-A1 | LABELING AGENT FOR ANALYZING POST-TRANSLATIONAL MODIFICATIONS OF SERINE AND THREONINE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2014-01-23 | — | — | US | disclosed |
| US-8465938-B2 | Method for producing complex of biotin-labeled Cypridina (Cypridina noctiluca) luciferase with streptoavidin and method for stabilizing the same | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLGY (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20120309040-A1 | DETECTION OF OXIDIZED POLYPEPTIDES | PURDUE RESEARCH FOUNDATION (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120077205-A1 | METHOD FOR PRODUCING COMPLEX OF BIOTIN-LABELED CYPRIDINA (CYPRIDINA NOCTILUCA) LUCIFERASE WITH STREPTOAVIDIN AND METHOD FOR STABILIZING THE SAME | OHMIYA YOSHIHIRO (JP) | 2012-03-29 | — | — | US | disclosed |
| US-20080241865-A1 | VISIBLE TO NEAR-INFRARED LIGHT PROBE COMPRISING COMPLEX OF CYPRIDINA LUCIFERASE AND QUANTUM DOT | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-10-02 | — | — | US | disclosed |
| US-20080241865-A1 | VISIBLE TO NEAR-INFRARED LIGHT PROBE COMPRISING COMPLEX OF CYPRIDINA LUCIFERASE AND QUANTUM DOT | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-10-02 | — | — | US | disclosed |
| US-20080108097-A1 | METHOD FOR PRODUCING COMPLEX OF BIOTIN-LABELED CYPRIDINA (CYPRIDINA NOCTILUCA) LUCIFERASE WITH STREPTOAVIDIN AND METHOD FOR STABILIZING THE SAME | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-05-08 | — | — | US | disclosed |
| US-20080108097-A1 | METHOD FOR PRODUCING COMPLEX OF BIOTIN-LABELED CYPRIDINA (CYPRIDINA NOCTILUCA) LUCIFERASE WITH STREPTOAVIDIN AND METHOD FOR STABILIZING THE SAME | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-05-08 | — | — | US | disclosed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070254006-A1 | Medical Devices and Coatings with Non-Leaching Antimicrobial Peptides | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2007-11-01 | — | — | US | disclosed |
| US-20030077616-A1 | Biomolecule characterization using mass spectrometry and affinity tags | CIPHERGEN BIOSYSTEMS, INC. (US) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254006-A1 | Medical Devices and Coatings with Non-Leaching Antimicrobial Peptides | HAMP, HM13, VIP | TDP1 3807/4885MEN1 875/4885ABL1 933/4885 |
| US-20240024489-A1 | PROTECTED DISACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE IN THE SYNTHESIS OF ZWITTERIONIC OLIGOSACCHARIDES, AND CONJUGATES THEREOF | SI, DAD1, FUT5 | TDP1 4698/4885MEN1 921/4885ABL1 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.